Celgene

Celgene was a biotechnology company focused on developing innovative therapies for serious diseases, particularly cancer and inflammatory conditions. It was known for its strong portfolio of drugs, such as Revlimid, used to treat multiple myeloma and other cancers. The company invested heavily in research to create targeted treatments that improved patient outcomes. In 2019, Celgene was acquired by Bristol-Myers Squibb, which integrated its products and research capabilities into its broader portfolio. Overall, Celgene played a significant role in advancing cancer and immune-related treatments through science-driven medication development.